PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
204 hedge funds and large institutions have $479M invested in PDL BioPharma, Inc. in 2015 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 79 increasing their positions, 57 reducing their positions, and 39 closing their positions.
258% more call options, than puts
Call options by funds: $1.17M | Put options by funds: $327K
39% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 57
4% less funds holding
Funds holding: 213 → 204 (-9)
18% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 39
59% less capital invested
Capital invested by funds: $1.18B → $479M (-$701M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$12M |
| 2 |
Goldman Sachs
New York
|
+$11M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$10.9M |
| 4 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
+$8.34M |
| 5 |
Millennium Management
New York
|
+$7.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Americafirst Capital Management
Roseville,
California
|
-$483M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$84.8M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$16M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$6.7M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$5.06M |
PDLI Hedge Fund Activity: Q4 2015 in Review
204 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q4 2015, worth a combined $479M — down 59% from $1.18B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of PDLI and 32 opened new positions — a net loss of 7 holders — while 57 trimmed existing stakes and 79 added.
The largest buyer was Mackenzie Financial, opening a new position worth an estimated $12M. The largest seller was Americafirst Capital Management, exiting entirely with an estimated $483M sold.
- 204 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q4 2015, down from 213 in Q3 2015.
- Funds reported $479M of PDL BioPharma, Inc. stock for Q4 2015, down 59% quarter-over-quarter.
- 32 funds opened new PDL BioPharma, Inc. positions in Q4 2015 and 39 closed out, a net change of -7 holders.
- The largest PDL BioPharma, Inc. buyer in Q4 2015 was Mackenzie Financial, an estimated $12M added.
- The largest PDL BioPharma, Inc. seller in Q4 2015 was Americafirst Capital Management, an estimated $483M sold.
Based on aggregated 13F filings for Q4 2015.